Jess Roland, DO
Pain Medicine · Omaha, NENPI 1497215875
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (46.4%), grants and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 91.8% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $4,576 and has fallen 89.1% since, to $501 in 2025.
Across 60 payments — averaging $127.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- SPR Therapeutics, Inc$446
- AbbVie$131
- Boston Scientific$18
- Si-bone, Inc.$16
- Merz North America, Inc.$13
What the payments were for
- Grants$2,50033%
- Travel & lodging$3,54246%
- Food & beverage$1,59921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 43 | $7,017 |
| SPR Therapeutics, Inc | 8 | $446 |
| AbbVie(2 entities) | 6 | $131 |
| Boston Scientific | 1 | $18 |
| Si-bone, Inc. | 1 | $16 |
| Merz North America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMEDII$2,500
- INTELLIS ADAPTIVESTIM$1,635
- VANTA ADAPTIVESTIM$1,494
- SPRINT PNS System$274
How this compares
$7,641 in reported general payments places this provider in the 60th percentile of 31 pain medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 13 | $783 |
| Gabapentin | 32 | $497 |
| Baclofen | 22 | $132 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Omaha
- Matthew StottleOmaha$14K
- Katie BerkyOmaha$12K
- Tyrus SoaresOmaha$8K
- Apollo StackOmaha$8K
- Marshall LaddOmaha$7K
- James DevneyOmaha$5K
- Peter PiperisOmaha$4K
- Dan NichollsOmaha$3K
- Ernesto PadronOmaha$3K
- Christopher CriscuoloOmaha$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.